AU2001229491A1 - Cyclic peptides as potent and selective melanocortin-4 receptor antagonists - Google Patents

Cyclic peptides as potent and selective melanocortin-4 receptor antagonists

Info

Publication number
AU2001229491A1
AU2001229491A1 AU2001229491A AU2949101A AU2001229491A1 AU 2001229491 A1 AU2001229491 A1 AU 2001229491A1 AU 2001229491 A AU2001229491 A AU 2001229491A AU 2949101 A AU2949101 A AU 2949101A AU 2001229491 A1 AU2001229491 A1 AU 2001229491A1
Authority
AU
Australia
Prior art keywords
potent
receptor antagonists
cyclic peptides
selective melanocortin
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001229491A
Other languages
English (en)
Inventor
Maria A. Bednarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2001229491A1 publication Critical patent/AU2001229491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2001229491A 2000-01-18 2001-01-16 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists Abandoned AU2001229491A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17650900P 2000-01-18 2000-01-18
US60176509 2000-01-18
PCT/US2001/001297 WO2001052880A1 (en) 2000-01-18 2001-01-16 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001229491A1 true AU2001229491A1 (en) 2001-07-31

Family

ID=22644637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001229491A Abandoned AU2001229491A1 (en) 2000-01-18 2001-01-16 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists

Country Status (6)

Country Link
US (1) US6693165B2 (ja)
EP (1) EP1251865A1 (ja)
JP (1) JP2003534240A (ja)
AU (1) AU2001229491A1 (ja)
CA (1) CA2396307A1 (ja)
WO (1) WO2001052880A1 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20030113263A1 (en) * 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US7130911B2 (en) * 2002-02-11 2006-10-31 Intel Corporation Method for monitoring unauthorized access to data stored in memory buffers
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1708755B1 (en) 2004-01-21 2012-03-21 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
WO2005103715A2 (en) * 2004-04-27 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
WO2007077112A1 (en) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Methods for the synthesis of arginine-containing peptides
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
NZ590254A (en) 2008-06-09 2012-07-27 Palatin Technologies Inc Melanocortin receptor-specific cyclic peptides for treatment of sexual dysfunction
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144344A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
EP2440572B1 (en) * 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
JP2013511554A (ja) 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA025380B1 (ru) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
PL422093A1 (pl) * 2017-07-03 2019-01-14 Uniwersytet Warszawski Nowe peptydomimetyki hybrydowe do zastosowań w bólu neuropatycznym
WO2019204496A1 (en) * 2018-04-19 2019-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating melanoma with a chimeric antigen receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
DE69738353T2 (de) 1996-07-12 2009-09-24 Immunomedics, Inc. Radiometall-bindende peptide analoge
CA2275442A1 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
US6228840B1 (en) 1998-02-27 2001-05-08 Edward T. Wei Melanocortin receptor antagonists and modulations of melanocortin receptor activity
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
KR100558131B1 (ko) 1999-03-29 2006-03-10 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드를 함유하는 약제학적 조성물및 멜라노코르틴 수용체 리간드를 함유하는 약제의제조방법

Also Published As

Publication number Publication date
US20020016291A1 (en) 2002-02-07
US6693165B2 (en) 2004-02-17
CA2396307A1 (en) 2001-07-26
WO2001052880A1 (en) 2001-07-26
JP2003534240A (ja) 2003-11-18
EP1251865A1 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
AU2001229491A1 (en) Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
SI1315750T1 (sl) Cikliäśni peptidi kot agonisti za receptorje melanokortina-4
AU2001250407A1 (en) Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
IL156304A0 (en) Cxcr3 antagonists
IL153308A0 (en) Thrombin receptor antagonists
AU2001280187A1 (en) Cyclic amine derivatives
WO2003006620A3 (en) Linear and cyclic melanocortin receptor-specific peptides
SG99324A1 (en) Microporous soundproofing material
AU2002366320A1 (en) Lactams as tachykinin antagonists
AU2001264657A1 (en) Crf receptor antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2441801A (en) Urotensin-ii receptor antagonists
EP1296958A4 (en) ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE
EP1178802A4 (en) CYCLIC AMIDINES HAVING GREAT UTILITY AS NMDA ANTAGONISTS
AU2001278626A1 (en) Tetrahydropyran derivatives as nk-1 receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2001249573A1 (en) Chemokine receptor antagonists
PL357875A1 (en) Cyclic hexapeptide derivatives
AU2002352388A1 (en) N-aroyl cyclic amine derivatives and their use as orxin receptor antagonist
AU6127498A (en) Msh-receptor subtype selective cyclic peptides
AU2574801A (en) Selective iGLUR5 receptor antagonists
AU2002220924A1 (en) Antibodies, peptides, analogs and uses thereof
EP1312612A4 (en) CYCLIC PEPTIDE DERIVATIVE
GB0307028D0 (en) Cyclic pentapeptides and their preparation
AU2002219319A1 (en) Modified tachykinin receptors